AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights positive financial performance with a 5% revenue increase and 10% rise in operating income, driven by strong demand in the Pharma segment. The company's strategic focus on market expansion and cost optimization supports a positive outlook. Despite potential risks like regulatory hurdles and supply chain disruptions, the overall sentiment is positive due to improved margins and financial metrics. The lack of negative sentiment in the Q&A section further supports a positive stock price movement prediction.
Key Financial Performance
Revenue Revenue for Q1 2026 was $900 million, representing a 5% increase year-over-year. The growth was driven by strong demand in the Pharma segment and favorable currency exchange rates.
Operating Income Operating income for the quarter was $150 million, up 10% compared to the same period last year. This increase was attributed to improved operational efficiencies and cost management.
Net Income Net income stood at $100 million, reflecting a 7% rise year-over-year. The improvement was due to higher revenue and better cost control measures.
Earnings Per Share (EPS) Earnings per share for Q1 2026 were $1.50, a 7% increase from the previous year, driven by the rise in net income.
Free Cash Flow Free cash flow was $80 million, up 15% year-over-year, primarily due to improved working capital management and higher operating cash flows.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company faces challenges in navigating complex regulatory environments, which could impact its ability to launch new products or maintain compliance with existing regulations.
Supply Chain Disruptions: Potential disruptions in the supply chain could affect the company's ability to deliver products on time, impacting customer satisfaction and financial performance.
Economic Uncertainties: Economic fluctuations and uncertainties could adversely affect consumer spending and demand for the company's products, impacting revenue and profitability.
Strategic Execution Risks: Challenges in executing strategic initiatives, such as mergers or expansions, could hinder the company's growth objectives and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: The focus is on expanding Aptar Pharma's market presence and enhancing product offerings.
Revenue Expectations: The company expects a mid-single-digit percentage increase in revenue for the full year 2026, driven by growth in the Pharma segment.
Margin Projections: Operating margins are anticipated to improve slightly due to cost optimization efforts and increased efficiency in production processes.
Capital Expenditures: Capital expenditures are projected to remain stable, with investments focused on capacity expansion and technological advancements.
Market Trends: The company anticipates a continued strong demand in the healthcare and pharma markets, with a gradual recovery in the beauty and home care segments.
Business Segment Performance: Pharma segment is expected to lead growth, while other segments are projected to recover gradually.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blair LLC
CEO President
CFO CEO
CFO Knight
Communications Hello
Communications Stephan
Division EDT
Division Gabe
Division George
Division Ghansham
Division Larew
Division Rizzo
Division Roberts
EDT Ladies
George Staphos
Ghansham Panjabi
Hello today
Inc Research
Knight KeyBanc
LLC Research
Larew Blair
Marry Skafidas
Panjabi Baird
President Executive
President press
Raymond Associates
Research Division
Roberts Raymond
Securities
Skafidas Vice
Staphos BofA
Stephan Tanda
Tanda President
conference Stephan
today Stephan
ATR Transcript
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call summary highlights positive financial performance with a 5% revenue increase and 10% rise in operating income, driven by strong demand in the Pharma segment. The company's strategic focus on market expansion and cost optimization supports a positive outlook. Despite potential risks like regulatory hurdles and supply chain disruptions, the overall sentiment is positive due to improved margins and financial metrics. The lack of negative sentiment in the Q&A section further supports a positive stock price movement prediction.
AptarGroup, Inc. (ATR) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Neutral3-3
AptarGroup, Inc. (ATR) Presents at Bank of America 2026 Global Agriculture and Materials Conference Transcript
Neutral2-25
AptarGroup, Inc. (ATR) Q4 2025 Earnings Call Transcript
Positive2-6
The earnings call summary and Q&A indicate positive sentiment: strong injectables demand, beauty and closures recovery, and strategic acquisitions. Despite emergency medicine headwinds, overall margins are expected to improve. The $600 million buyback authorization and $100 million cost savings initiatives are additional positives. Although management avoided specific guidance, the overall outlook remains optimistic, justifying a positive stock price reaction.
ATR Slides
ATR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
